Dr Quatrini and colleagues evaluated the clinical history of a series of patients with Zollinger-Ellison syndrome in the period 1966 to 2002.
The investigative team considered patients before and after the introduction of the current antisecretive
H2 receptor antagonists and proton pump inhibitors into clinical practice.
The team involved 18 patients with Zollinger-Ellison syndrome of which 9 were males, with a mean age of 43 years.
8 patients were diagnosed with Type 1 multiple endocrine neoplasia, on the basis of standard criteria.
|Total gastrectomy and compliance to antisecretory treatment reduced operations from 29 to 9|
|Journal of Clinical Gastroenterology|
The researchers considered the type, number and effectiveness of surgical interventions before and after appropriate treatment.
In addition, the research team looked at the localization of the gastrinoma, the presence of associated diseases, the causes of death, and the duration of survival.
The researchers found that total gastrectomy (but not antrectomy and vagotomy) and full compliance to antisecretory treatment reduced the number of operations from 29 to 9.
The investigators reported that 1 patient was cured, whereas relapsing gastrinomas occurred in 4 patients and associated diseases or complications in 10.
Death was related to Zollinger-Ellison syndrome in 5 patients and to other causes in 4.
Dr Quatrini’s team concludes, “Curing gastrinoma or appropriately inhibiting gastric acid hypersecretion in patients Zollinger-Ellison syndrome prevents death.”
“The cure or inhibition of gastric acid hypersecretion also favors long-term survival, regardless of gastrin levels and the size or number of tumors.”